Eclipta Alba, An Antioxidant-Rich Memory Enhancer: In-Silico and In-Vivo Evidence with Specific Insight into Alzheimer’s Disease

The study investigates Eclipta alba (EA) as a potential treatment for Alzheimer's disease (AD) by identifying its secondary metabolites and their interactions with AD-related proteins. Using liquid chromatography-mass spectrometry (LC-MS), the study found significant amounts of compounds like Lilaline, Laccarin, and Coriandrone E, with the latter showing the highest binding affinity in autodocking analysis. In vivo tests on albino Wistar rats, administered 150 mg/kg of EA for 28 days, demonstrated improved memory performance without significant toxicity. The findings suggest that EA could influence cholinergic neurons by regulating acetylcholine esterase activity, offering a promising alternative to current commercial inhibitors for AD treatment.